Compare Enovix Corporation (ENVX) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs TransMedics Group Inc — how do they compare? Enovix Corporation trades at $4.9 (market cap $1.06B), while TransMedics Group Inc trades at $86.28 (market cap $3.10B). The key difference: TransMedics Group Inc is far larger — about 2.9× Enovix Corporation's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals.
| ENVX | TMDX | |
|---|---|---|
Market Cap | $1.06B | $3.10B |
Sector | Technology | Technology |
52-Week High | $13.19 | $150.42 |
52-Week Low | $3.68 | $61.99 |
Enterprise Value | $1.07B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $4.92, up 6.03% in the last 24 hours, with a bullish technical signal despite negative profitability. Recent earnings beats and the appointment of a former Apple executive as COO highlight operational progress. The stock shows strong analyst support with a consensus price target of $12.38, though cash flow remains negative as the company scales production.
Outlook is cautiously optimistic given high growth potential in advanced battery technology, but significant execution risks and persistent losses require careful monitoring. The stock offers upside if production ramps successfully, but volatility may persist near-term.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
